Tasidotin hydrochloride
DRACPC ID DRACPC0105
Active Ingredients Tasidotin hydrochloride
Description A synthetic analogue of dolastatin 15. Dolastatins are a group of structurally unique peptides originally isolated from a sea hare, Dolabella auricularia, which seem to inhibit tubulin polymerization and mitosis.
Synonyms ILX-651; Tasidotin HCl; Tasidotin Hydrochloride
Type Small Molecule
Disease Melanoma,Non-Small-Cell Lung Carcinoma, Prostate Cancer
Classification
Peptide and derivative
Structure Information
Molecular Formula C32H59ClN6O5
Molecular Weight 643.3
Active Sequence VVXPP
Sequence Length 5
Modification X=N(Me)Val, C-terminal Me2, N-terminal NHtBu.HCl
IUPAC Name (2S)-N-tert-butyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride
InChI InChI=1S/C32H58N6O5.ClH/c1-19(2)24(33-28(40)25(20(3)4)35(10)11)30(42)36(12)26(21(5)6)31(43)38-18-14-16-23(38)29(41)37-17-13-15-22(37)27(39)34-32(7,8)9;/h19-26H,13-18H2,1-12H3,(H,33,40)(H,34,39);1H/t22-,23-,24+,25-,26-;/m0./s1
InChI_Key OOKIODJYZSVHDO-JJMGAAHBSA-N
SMILES CC(C)[C@H](N(C)C)C(N[C@H](C(C)C)C(N(C)[C@H](C(N(CCC1)[C@]1([H])C(N2CCC[C@]([H])2C(NC(C)(C)C)=O)=O)=O)C(C)C)=O)=O.[H]Cl
External Codes
PubChem CID 11479259
DrugBank Accession Number Not available
NCI Thesaurus Code C142999
UNII 3382C833Z5 GSRS
CAS 623174-20-9
Drug approval
Drug indication
Investigated for use/treatment in Melanoma,Non-Small-Cell Lung Carcinoma, Hormone-refractory Prostate Cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00068211 | A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Inoperable Locally Advanced or Metastatic Melanoma. | Melanoma | Phase 2 | Treatment |
| NCT00082134 | A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Every 21 Days in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel | Hormone-refractory Prostate Cancer | Phase 2 | Treatment |
| NCT00078455 | A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma | Non-Small-Cell Lung Carcinoma | Phase 2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
